[Recent Advances in SARS-CoV-2-Induced Immune Thrombocytopenia --Review].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
; 31(2): 593-597, 2023 Apr.
Article
in Chinese
| MEDLINE | ID: covidwho-2320913
ABSTRACT
SARS-CoV-2-induced immune thrombocytopenia (SARS-CoV-2-induced ITP) is an autoimmune disease secondary to virus infections. Its diagnosis is often based on exclusion of other possible causes of thrombocytopenia in COVID-19 patients. Common laboratory examinations include coagulation function, thrombopoietin and drug-dependent antibodies. Since both bleeding and thrombosis risks are seen in SARS-CoV-2-induced ITP patients, individual remedy is essential for the treatment of this disease. Because thrombopoietin receptor agonist(TPO-RA) has the side effect of accelerating thrombosis and may aggravate the pulmonary embolism symptoms of patients, it should be used for refractory SARS-CoV-2-induced ITP patients only. This review briefly summarizes the recent research progress in the pathogenesis, diagnosis and treatment of SARS-CoV-2-induced ITP.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Thrombocytopenia
/
Thrombosis
/
Purpura, Thrombocytopenic, Idiopathic
/
COVID-19
Type of study:
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
Chinese
Journal:
Zhongguo Shi Yan Xue Ye Xue Za Zhi
Journal subject:
Hematology
Year:
2023
Document Type:
Article
Affiliation country:
J.cnki.issn.1009-2137.2023.02.042
Similar
MEDLINE
...
LILACS
LIS